Rafael Rios

Majadahonda, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 01, 2024

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Journal: Blood

Published: April 16, 2024

Children with obesity have poorer circadian health as assessed by a global circadian health score.

Children with obesity have poorer circadian health as assessed by a global circadian health score.

Journal: World journal of pediatrics : WJP

Published: September 06, 2023

Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.

Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 18, 2023

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 17, 2023

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Journal: Blood

Published: December 28, 2022

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 06, 2022

Oral Acid Load Down-Regulates Fibroblast Growth Factor 23.

Oral Acid Load Down-Regulates Fibroblast Growth Factor 23.

Journal: Nutrients

Published: January 26, 2022

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 14, 2022

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

Journal: Blood cancer journal

Published: January 11, 2022

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.

Journal: Blood cancer journal

Published: December 22, 2021

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.

Journal: Blood advances

Published: December 03, 2021

Showing 1-12 of 56

Last Updated: 09/26/2026